[1] 中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会,等. 原发性肝癌规范化病理诊断指南(2015年版).中华肝胆外科杂志,2015,21:144-145.
[2] Gu XQ,Zheng WP,Teng DH,et al. Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients.World J Gastroenterol,2016, 22:2749-2759.
[3] 张萌,叶啟发,钟自彪,等.原发性肝癌肝移植的研究进展.中华消化外科杂志,2017,16:215-220.
[4] Ng KT,Lo CM,Wong N,et al. Early-phase circulating miRNAs predict tumor recurrence and survival of hepatocellular carcinoma patients after liver transplantation.Oncotarget,2016,7:19824-19839.
[5] 武晓勇,张燕忠,张彧,等.射频消融术联合索拉菲尼治疗原发性肝癌的效果观察.中国医药,2016,11:688-690.
[6] 吴友祥,路远,晏彬,等.血清白细胞介素-35水平对索拉菲尼联合非规则性肝切除术治疗的原发性肝癌患者临床疗效及预后的影响.广西医学,2017,39:782-785.
[7] Du GS,Zhou L,Shi BY,et al. Clinical study of triple anti-tumor therapy for preventing tumor recurrence of terminal primary liver cancer after liver transplantation.Organ Transplantation,2014,5:74-78.
[8] Zahavi T,Lanton T,Divon MS,et al. Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model.Oncotarget,2016,7:4860-4870.
[9] 陈建斌,陈国勇,孙建军,等.索拉非尼治疗肝癌肝移植术后肿瘤复发的临床疗效观察.器官移植,2013,4:98-101. |
